Understanding Alzheimer disease

South African Family Practice

Field Value
Title Understanding Alzheimer disease
Creator Vally, M. Kathrada, F.
Subject — dementia; Alzheimer disease; treatment of dementia; risk factors; management of Alzheimer disease
Description Alzheimer disease (AD) is a neurodegenerative disorder with an uncertain pathogenesis. It is characterised by symptoms of memory impairment, executive dysfunction and visuospatial impairment. Management goals and interventions should be based on a solid alliance with the patient and family and on thorough psychiatric, neurological and general medical evaluations of the nature and cause of cognitive deficits and associated non-cognitive symptoms. There are currently three cholinesterase inhibitors and one N-methyl-D-aspartate (NMDA) antagonist indicated in the treatment of AD as monotherapy or in combination. Cholinesterase inhibitors remain the first-line therapy in patients with mild to moderate AD, which may stabilise the symptomatic cognitive and functional decline. Other pharmacotherapy options include the use of memantine which may be used by itself or in combination with cholinesterase inhibitors. These treatments are for symptomatic relief and are not disease modifying in preventing the progression of the disease.
Publisher AOSIS
Date 2019-04-29
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Peer-reviewed Article —
Format application/pdf
Identifier 10.4102/safp.v61i2.4999
Source South African Family Practice; Vol 61, No 2 (2019): March/April; 28-34 2078-6204 2078-6190
Language eng
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

Coverage — — —
Rights Copyright (c) 2019 M. Vally, F. Kathrada https://creativecommons.org/licenses/by/4.0